138 related articles for article (PubMed ID: 32242147)
1. Feedback activation of EGFR is the main cause for STAT3 inhibition-irresponsiveness in pancreatic cancer cells.
Zhao C; Yang L; Zhou F; Yu Y; Du X; Xiang Y; Li C; Huang X; Xie C; Liu Z; Lin J; Wang L; Liang G; Cui R
Oncogene; 2020 May; 39(20):3997-4013. PubMed ID: 32242147
[TBL] [Abstract][Full Text] [Related]
2. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Lamichhane P; Messaggio F; Shi C; Dai X; Rai P; Chen X; VanSaun MN; Merchant NB
Cancer Res; 2018 Nov; 78(21):6235-6246. PubMed ID: 30154150
[TBL] [Abstract][Full Text] [Related]
3. Rhein sensitizes human pancreatic cancer cells to EGFR inhibitors by inhibiting STAT3 pathway.
Yang L; Lin S; Kang Y; Xiang Y; Xu L; Li J; Dai X; Liang G; Huang X; Zhao C
J Exp Clin Cancer Res; 2019 Jan; 38(1):31. PubMed ID: 30674340
[TBL] [Abstract][Full Text] [Related]
4. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
Kim SM; Kwon OJ; Hong YK; Kim JH; Solca F; Ha SJ; Soo RA; Christensen JG; Lee JH; Cho BC
Mol Cancer Ther; 2012 Oct; 11(10):2254-64. PubMed ID: 22891040
[TBL] [Abstract][Full Text] [Related]
5. STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics.
Zulkifli AA; Tan FH; Putoczki TL; Stylli SS; Luwor RB
Mol Cell Endocrinol; 2017 Aug; 451():15-23. PubMed ID: 28088467
[TBL] [Abstract][Full Text] [Related]
6. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells.
Lee HJ; Zhuang G; Cao Y; Du P; Kim HJ; Settleman J
Cancer Cell; 2014 Aug; 26(2):207-21. PubMed ID: 25065853
[TBL] [Abstract][Full Text] [Related]
7. Enhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src.
Jaganathan S; Yue P; Turkson J
J Pharmacol Exp Ther; 2010 May; 333(2):373-81. PubMed ID: 20100905
[TBL] [Abstract][Full Text] [Related]
8. Inflammation-induced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D.
Baumgart S; Chen NM; Siveke JT; König A; Zhang JS; Singh SK; Wolf E; Bartkuhn M; Esposito I; Heßmann E; Reinecke J; Nikorowitsch J; Brunner M; Singh G; Fernandez-Zapico ME; Smyrk T; Bamlet WR; Eilers M; Neesse A; Gress TM; Billadeau DD; Tuveson D; Urrutia R; Ellenrieder V
Cancer Discov; 2014 Jun; 4(6):688-701. PubMed ID: 24694735
[TBL] [Abstract][Full Text] [Related]
9. Alantolactone sensitizes human pancreatic cancer cells to EGFR inhibitors through the inhibition of STAT3 signaling.
Zheng H; Yang L; Kang Y; Chen M; Lin S; Xiang Y; Li C; Dai X; Huang X; Liang G; Zhao C
Mol Carcinog; 2019 Apr; 58(4):565-576. PubMed ID: 30520143
[TBL] [Abstract][Full Text] [Related]
10. STAT3 mediated upregulation of C-MET signaling acts as a compensatory survival mechanism upon EGFR family inhibition in chemoresistant breast cancer cells.
Zhu Y; Zhang H; Han X; Wang Z; Cui Y; Tian R; Wang Z; Han B; Tian J; Zhang F; Niu R
Cancer Lett; 2021 Oct; 519():328-342. PubMed ID: 34348188
[TBL] [Abstract][Full Text] [Related]
11. Circular RNA ciRS-7 promotes the proliferation and metastasis of pancreatic cancer by regulating miR-7-mediated EGFR/STAT3 signaling pathway.
Liu L; Liu FB; Huang M; Xie K; Xie QS; Liu CH; Shen MJ; Huang Q
Hepatobiliary Pancreat Dis Int; 2019 Dec; 18(6):580-586. PubMed ID: 30898507
[TBL] [Abstract][Full Text] [Related]
12. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
[TBL] [Abstract][Full Text] [Related]
13. EGFR High Expression, but not KRAS Status, Predicts Sensitivity of Pancreatic Cancer Cells to Nimotuzumab Treatment In Vivo.
Zhou C; Zhu L; Ji J; Ding F; Wang C; Cai Q; Yu Y; Zhu Z; Zhang J
Curr Cancer Drug Targets; 2017; 17(1):89-97. PubMed ID: 27739365
[TBL] [Abstract][Full Text] [Related]
14. Induction of apoptosis by morusin in human non-small cell lung cancer cells by suppression of EGFR/STAT3 activation.
Park HJ; Min TR; Chi GY; Choi YH; Park SH
Biochem Biophys Res Commun; 2018 Oct; 505(1):194-200. PubMed ID: 30243717
[TBL] [Abstract][Full Text] [Related]
15. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
16. Mutant KRAS Downregulates the Receptor for Leukemia Inhibitory Factor (LIF) to Enhance a Signature of Glycolysis in Pancreatic Cancer and Lung Cancer.
Liu S; Gandler HI; Tošić I; Ye DQ; Giaccone ZT; Frank DA
Mol Cancer Res; 2021 Aug; 19(8):1283-1295. PubMed ID: 33931487
[TBL] [Abstract][Full Text] [Related]
17. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY
Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318
[TBL] [Abstract][Full Text] [Related]
18. A functional nuclear epidermal growth factor receptor, SRC and Stat3 heteromeric complex in pancreatic cancer cells.
Jaganathan S; Yue P; Paladino DC; Bogdanovic J; Huo Q; Turkson J
PLoS One; 2011 May; 6(5):e19605. PubMed ID: 21573184
[TBL] [Abstract][Full Text] [Related]
19. Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells.
Fitzgerald TL; Lertpiriyapong K; Cocco L; Martelli AM; Libra M; Candido S; Montalto G; Cervello M; Steelman L; Abrams SL; McCubrey JA
Adv Biol Regul; 2015 Sep; 59():65-81. PubMed ID: 26257206
[TBL] [Abstract][Full Text] [Related]
20. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.
Wen W; Wu J; Liu L; Tian Y; Buettner R; Hsieh MY; Horne D; Dellinger TH; Han ES; Jove R; Yim JH
Mol Cancer; 2015 May; 14():100. PubMed ID: 25928246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
